WalterWChathamMD

Rheumatology • Las Vegas, NV

Lupus & Related, Vasculitis

Physician

Join to view full profile

Dr. Chatham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chatham's full profile

Already have an account?

Office
1707 W Charleston Blvd
Ste 230
Las Vegas, NV 89102
Phone+1 702-671-6469

Summary

Rheumatology section head

Education & Training

University of Alabama Medical CenterFellowship, Rheumatology, 1986 - 1989
University of North Carolina HospitalsResidency, Internal Medicine, 1980 - 1983
Vanderbilt University School of MedicineClass of 1980
Duke UniversityBSE, Biomedical Engineering, Summa Cum Laude, 1972 - 1976

Certifications & Licensure

NV State Medical License 2023 - 2025
AL State Medical License 1986 - 2024
FL State Medical License 2018 - 2022
TN State Medical License 1983 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Rituximab and Belimumab for Lupus Nephritis Start of enrollment: 2015 Jul 09
Completed
Phase 2
Treatment of Macrophage Activation Syndrome (MAS) With Anakinra Start of enrollment: 2016 May 15
Active, not recruiting
Phase 1
Early Treatment of Cytokine Storm Syndrome in Covid-19 Start of enrollment: 2020 Aug 01
Completed
Phase 3

Publications & Presentations

PubMed

1068 citations
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie, Michelle A. Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace
Arthritis and Rheumatism. 2011-12-01
937 citations
American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar, Jeremy Anuntiyo, Catherine Finney
Arthritis and Rheumatism. 2008-06-15
1158 citations
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of r...
Jasvinder A. Singh, Daniel E. Furst, Aseem Bharat, Jeffrey R. Curtis, Arthur Kavanaugh
Arthritis Care & Research. 2012-05-01

Journal Articles

Cutting Edge: Intracellular IFN-Β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells
W Winn Chatham, John D Mountz, Ignacio Sanz, The Journal of Immunology